Sequana Medical N.V.
ISIN: BE0974340722 | Ticker: SEQUA | LEI: 8755009AN12Y4PEOII07
Country: Belgium
We are pioneers in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. Fluid overload is a well-recognized problem in these growing diseases, causing severe problems for the large number of patients for whom current medicines are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficult breathing and restricted mobility that severely impacts daily life.
alfapump® and DSR® are our proprietary platforms that work with the body to remove this excess fluid, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems.
We are listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium.
2006
Served areaWorldwide
HeadquartersKortrijksesteenweg 1112, 9051 Sint-Denijs-Westrem, Oost-Vlaanderen – Belgium
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 02.01.2021 | 01.01.2022 | 02.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|---|
| Assets | N/A | 14,213,451.00 | N/A | 14,705,221.00 | N/A | 26,025,232.00 |
| Noncurrent Assets | N/A | 772,023.00 | N/A | 1,814,560.00 | N/A | 2,935,911.00 |
| Property Plant And Equipment | N/A | 704,718.00 | N/A | 1,268,338.00 | N/A | 2,067,958.00 |
| Other Noncurrent Assets | N/A | 0.00 | N/A | 463,860.00 | N/A | 782,207.00 |
| Current Assets | N/A | 13,441,429.00 | N/A | 12,890,660.00 | N/A | 23,089,321.00 |
| Inventories | N/A | 1,471,655.00 | N/A | 2,139,425.00 | N/A | 2,621,197.00 |
| Current Trade Receivables | N/A | 23,625.00 | N/A | 81,882.00 | N/A | 113,871.00 |
| Current Prepaid Expenses | N/A | 616,407.00 | N/A | 767,696.00 | N/A | 1,186,964.00 |
| Other Current Receivables | N/A | 313,598.00 | N/A | 301,244.00 | N/A | 292,330.00 |
| Cash and cash equivalents | 5,586,470.00 | 11,016,143.00 | N/A | 9,600,412.00 | N/A | 18,874,959.00 |
| Equity And Liabilities | N/A | 14,213,451.00 | N/A | 14,705,221.00 | N/A | 26,025,232.00 |
| Equity | 925,932.00 | 112,761.00 | 112,761.00 | -786,919.00 | -786,919.00 | -2,153,252.00 |
| Issued Capital | N/A | 1,635,006.00 | N/A | 1,924,932.00 | N/A | 2,460,487.00 |
| Retained Earnings | N/A | -119,080,220.00 | N/A | -142,695,301.00 | N/A | -173,458,384.00 |
| Share Premium | N/A | 119,332,864.00 | N/A | 142,432,715.00 | N/A | 170,324,139.00 |
| Other Reserves | N/A | -2,250,413.00 | N/A | -2,668,955.00 | N/A | -2,425,934.00 |
| Noncurrent Liabilities | N/A | 8,134,686.00 | N/A | 8,311,998.00 | N/A | 13,030,481.00 |
| Noncurrent Recognised Liabilities Defined Benefit Plan | N/A | 539,042.00 | N/A | 509,851.00 | N/A | 228,194.00 |
| Longterm Borrowings | N/A | 7,472,701.00 | N/A | 7,324,835.00 | N/A | 12,192,829.00 |
| Current Liabilities | N/A | 5,966,004.00 | N/A | 7,180,142.00 | N/A | 15,148,003.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 2,013,178.00 | N/A | 2,192,903.00 | N/A | 3,227,290.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | N/A | 2,522,065.00 | N/A | 3,514,543.00 |
| Current Contract Liabilities | N/A | 789,311.00 | N/A | 174,207.00 | N/A | 164,492.00 |
| Other Current Payables | N/A | 1,523,426.00 | N/A | 1,924,597.00 | N/A | 1,811,940.00 |
| Other Current Financial Liabilities | N/A | N/A | N/A | 0.00 | N/A | 1,568,784.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 0.00 | N/A | 0.00 | N/A | 4,482,914.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 963,280.00 | 370,500.00 | 922,687.00 |
| Other Income | 41,467.00 | 1,204,996.00 | 530,174.00 |
| Profit Loss From Operating Activities | -17,771,117.00 | -22,613,644.00 | -28,094,484.00 |
| Finance Income | 169,547.00 | 246,384.00 | 450,553.00 |
| Finance Costs | 1,347,609.00 | 854,549.00 | 2,732,522.00 |
| Income Tax Expense Continuing Operations | 157,025.00 | 393,272.00 | 386,629.00 |
| Profit (loss) | -19,106,205.00 | -23,615,081.00 | -30,763,083.00 |
| Profit Loss Attributable To Owners Of Parent | -19,106,205.00 | -23,615,081.00 | -30,763,083.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -19,106,205.00 | -23,615,081.00 | -30,763,083.00 |
| Adjustments For Income Tax Expense | N/A | 157,025.00 | 393,272.00 | 386,629.00 |
| Adjustments For Finance Costs | N/A | 1,046,846.00 | 612,541.00 | 1,923,083.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 125,968.00 | -864,873.00 | 42,417.00 |
| Adjustments For Sharebased Payments | N/A | 255,860.00 | 536,389.00 | 564,440.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 36,404.00 | 221,943.00 | 378,111.00 |
| Cash Flows From Used In Operating Activities | N/A | -17,005,228.00 | -23,617,366.00 | -27,481,845.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 138,017.00 | 325,782.00 | 676,736.00 |
| Cash Flows From Used In Investing Activities | N/A | -142,031.00 | -338,201.00 | -653,092.00 |
| Proceeds From Issuing Shares | N/A | 18,999,996.00 | 22,770,861.00 | 28,419,974.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 7,300,000.00 | 0.00 | 9,626,085.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 3,201,376.00 | 0.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 273,690.00 | 335,369.00 | 407,217.00 |
| Interest Paid Classified As Financing Activities | N/A | 194,395.00 | 0.00 | 314,516.00 |
| Cash Flows From Used In Financing Activities | N/A | 22,630,535.00 | 22,435,491.00 | 37,324,326.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 5,483,275.00 | -1,520,075.00 | 9,189,389.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -53,602.00 | 104,344.00 | 85,158.00 |
| Cash and cash equivalents | 5,586,470.00 | 11,016,143.00 | 9,600,412.00 | 18,874,959.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 04.06.21 | Fin-2K BV | Executive member | Buy | EUR 0.00 |
| 27.05.21 | Crosbie Ian | Board | Buy | EUR 0.00 |
| 07.09.20 | Fin-2K BV | Executive member | Buy | EUR 0.00 |
| 04.09.20 | Crosbie Ian | Board | Buy | EUR 0.00 |
| 06.06.19 | wim ottevaere | Board | Buy | EUR 25,600.00 |
| 29.03.19 | Fin-2K BV | Executive member | Buy | EUR 0.00 |
| 06.03.19 | Crosbie Ian | Board | Buy | EUR 0.00 |
| 26.02.19 | Chauvineau Pierre | Board | Buy | EUR 0.00 |
| 13.02.19 | wim ottevaere | Board | Buy | EUR 49,345.10 |
BE0974340722
LEI8755009AN12Y4PEOII07
SectorHealth Care Equipment & Services
IndustryHealth Care Equipment & Supplies
Sub-IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.